Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 5/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | FLT3 | P36888 | 2/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | LTK | P29376 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17278412 | 0.86 | KCNA5 (0.39) | KCNA5CA2GABRA1GABRB2KDR | |
| SCHEMBL17030757 | 0.80 | KDR (0.50) | KCNA5CA2KDRFLT3CHEK1 | |
| SCHEMBL25592125 | 0.77 | KCNA5 (0.35) | KCNA5CA2GABRA1GABRB2KDR | |
| SCHEMBL8404487 | 0.76 | CYP1A2 (0.41) | KDRFLT3CHEK1MAP4K4ABL1 | |
| SCHEMBL27176591 | 0.76 | P2RX7 (0.36) | KCNA5KDRFLT3AURKBKIT | |
| SCHEMBL26190221 | 0.73 | CA2 (0.48) | CA2GABRA1GABRB2ALDH1A1NPSR1 | |
| SCHEMBL3195416 | 0.73 | KCNA5 (0.46) | KCNA5KDRFLT3CHEK1MAP4K4 | |
| SCHEMBL29314341 | 0.73 | KDR (0.38) | KCNA5KDRFLT3CHEK1MAP4K4 | |
| SCHEMBL21783714 | 0.73 | KDR (0.45) | KDRFLT3CHEK1MAP4K4ABL1 | |
| SCHEMBL21807299 | 0.73 | KDR (0.38) | KDRFLT3CHEK1MAP4K4ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| WO-2023088406-A1 | FUSED IMIDE DERIVATIVE | 正大天晴药业集团股份有限公司 | 2023-05-25 | — | — | WO | disclosed |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-05-03 | — | — | US | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
| US-20100160292-A1 | Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors | CGI PHARMACEUTICALS, INC (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160292-A1 | Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors | BTK, LYN, LCK | KCNA5 2786/4885CA2 3080/4885GABRA1 2385/4885 |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KCNA5 3260/4885CA2 1657/4885GABRA1 4063/4885 |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KCNA5 3396/4885CA2 1729/4885GABRA1 3618/4885 |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | KCNA5 4779/4885CA2 2496/4885GABRA1 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.